Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,568,183
  • Shares Outstanding, K 129,388
  • Annual Sales, $ 660,570 K
  • Annual Income, $ -78,730 K
  • EBIT $ -121 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.60
  • Price/Sales 2.36
  • Price/Cash Flow 27.51
  • Price/Book 1.86

Options Overview Details

View History
  • Implied Volatility 153.46% (+89.29%)
  • Historical Volatility 47.05%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 153.46% on 12/04/25
  • IV Low 31.11% on 12/10/24
  • Expected Move (DTE 14) 1.47 (12.08%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 204
  • Volume Avg (30-Day) 421
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 27,539
  • Open Int (30-Day) 31,175
  • Expected Range 10.70 to 13.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.06
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.71 +25.33%
on 11/14/25
12.51 -2.68%
on 11/25/25
+2.07 (+20.50%)
since 11/04/25
3-Month
7.36 +65.35%
on 09/10/25
12.51 -2.68%
on 11/25/25
+4.11 (+50.99%)
since 09/04/25
52-Week
4.72 +157.84%
on 08/01/25
19.11 -36.33%
on 01/08/25
-5.84 (-32.43%)
since 12/04/24

Most Recent Stories

More News
3 Overrated Stocks That Concern Us

3 Overrated Stocks That Concern Us

MOV : 20.94 (-1.27%)
EXAS : 101.13 (-0.12%)
NEO : 12.17 (+0.41%)
1 Cash-Burning Stock to Research Further and 2 We Brush Off

1 Cash-Burning Stock to Research Further and 2 We Brush Off

LEN : 126.75 (-4.79%)
NEO : 12.17 (+0.41%)
SMRT : 1.8800 (+3.30%)
NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know

NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know

FTRE : 14.50 (-0.55%)
ACHC : 14.64 (-0.34%)
NEO : 12.17 (+0.41%)
1 High-Flying Stock on Our Buy List and 2 We Find Risky

1 High-Flying Stock on Our Buy List and 2 We Find Risky

APP : 683.78 (+3.26%)
NEO : 12.17 (+0.41%)
WMT : 114.84 (+0.38%)
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

CROX : 88.24 (-1.24%)
NEO : 12.17 (+0.41%)
HOMB : 28.52 (+0.21%)
3 Volatile Stocks We Keep Off Our Radar

3 Volatile Stocks We Keep Off Our Radar

COUR : 8.37 (+0.12%)
NEO : 12.17 (+0.41%)
DAY : 69.11 (+0.01%)
NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: ...

NEO : 12.17 (+0.41%)
The Top 5 Analyst Questions From NeoGenomics’s Q3 Earnings Call

The Top 5 Analyst Questions From NeoGenomics’s Q3 Earnings Call

NEO : 12.17 (+0.41%)
NeoGenomics (NEO): Buy, Sell, or Hold Post Q3 Earnings?

NeoGenomics (NEO): Buy, Sell, or Hold Post Q3 Earnings?

NEO : 12.17 (+0.41%)
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors

NEO : 12.17 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

3rd Resistance Point 12.63
2nd Resistance Point 12.44
1st Resistance Point 12.31
Last Price 12.17
1st Support Level 11.99
2nd Support Level 11.80
3rd Support Level 11.67

See More

52-Week High 19.11
Fibonacci 61.8% 13.62
Last Price 12.17
Fibonacci 50% 11.92
Fibonacci 38.2% 10.22
52-Week Low 4.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar